Nasdaq GlobeNewswire

Aurora Provides Update on Market and Strategic Product Initiatives

Del

Aurora Solar Technologies Inc. / Aurora Provides Update on Market and Strategic Product Initiatives . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement.

NORTH VANCOUVER, British Columbia, Jan. 25, 2018 (GLOBE NEWSWIRE) -- Following recent commercial wins in the explosively growing market for advanced PV cells and modules, Aurora Solar Technologies Inc. ("Aurora")("Company")(TSX.V:ACU) (OTCBB:AACTF) (FSE:A82) provides an update on further initiatives to consolidate and expand the company's position in the industry.

Global Market Expansion

With the price of solar energy dropping from $6 per watt to less than $1 per watt in the past 8 years, the outlook for solar energy as an alternative to dirty fossil fuels has never looked brighter. Driving this cost reduction is the launch of new, innovative solar cell designs and processes which could see the market size triple by 2020 (greentechmedia.com). This growth is being driven by investments in clean energy from emerging markets such as China and India where heavy air pollution in major cities is a key strategic problem as well as from leading Western countries such as the U.S., Japan, UK and Canada, and the European Union.

The new solar cell designs such as Monocrystalline PERC, Bifacial and Heterojunction technology are leading the way in improving margins and productivity for cell producers. With significant investments in these three areas by the leading global producers of solar cells, more than 80% of installed solar cell capacity are expected to reflect these designs within the next 7 years (thequartzcorp.com).

Addressing new high-efficiency solar cell markets.

Over the past two years, Aurora has successfully launched Decima and Gemini quality measurement platforms to support Monocrystalline PERC and Bifacial applications. The company has delivered more than 50 of these systems to leaders in the market and continues to expand its customer base and order book by establishing infrared quality measurement as a standard in all new production lines.

As part of the company's leadership strategy in production measurement and control for high-efficiency PV cell manufacturing, Aurora has recently made excellent progress in developing its infrared measurement technology to support Heterojunction Technology (HJT) PV cell manufacturing quality control. (HJT is an ultra high-efficiency solar cell design pioneered by Japan's Panasonic Corp., who is now also partnered with Tesla Inc. for solar products). According to Solar Media Ltd., HJT production capacity is expected to increase by 20 percent this year.

To accelerate this work, Aurora is collaborating with the Solar Energy Research Institute of Singapore (SERIS). SERIS, located at the National University of Singapore, is Singapore's national institute for applied solar energy research, and has strong expertise in HJT R&D.

"SERIS places great value on working with innovative industry partners such as Aurora," said Dr. Armin Aberle, SERIS' CEO. "With our scientific expertise in PV cell design and performance, and our advanced fabrication and analysis facilities, we can assist Aurora in the sophisticated technology development necessary to quickly and effectively address high-growth market segments such as HJT."

Dr. Thomas MUELLER, Head of SERIS' Heterojunction R&D activities, added "We appreciate the opportunity to work with Aurora on developing rapid inline metrology tools to analyse solar cell doped layer carrier concentrations using infrared technology. The ability to gather this information at a large sampling rate in a non-destructive way will lead to much faster process optimization, tighter process control, and higher yield in PV production than is possible with today's probing techniques."

Alignment with Industry 4.0.

Aurora has also aligned its Veritas(TM) visualization, operations and administration system with the emerging Industry 4.0 initiatives in the PV industry. "Industry 4.0" refers to "smart factories" that will ultimately incorporate sensors at every stage of the manufacturing process, cloud computing and cognitive computing for fine-grained process and quality control. According to Dr. Gisela Lanza, Director of the Global Advanced Manufacturing Institute in Suzhou, China, "In China, particularly, there is enormous receptiveness for Industry 4.0. The predominant attitude there is, if I'm investing, then I'm going to spend my money on the very latest technology." This is exemplified by Tongwei Group's recent launch of their 2 Gigawatt "S2" production facility, which they claim to include the world's first Industry 4.0 solar cell production line. In Veritas, Aurora provides facility-wide connectivity to multiple sensors, intelligent display and analysis of process performance and open communication with factory control and resource management systems. The company is also conducting work with leading PV manufacturers to further develop high-value features in Veritas that support Industry 4.0.

Increased capital spending focused on high efficiency solar cell upgrades.

Overall, the Company is observing and benefiting from an unprecedented increase in capital spending focused on the adoption of advanced solar cell structures including Monocrystalline PERC, Bifacial and HJT PV cells.

Finlay Colville, Head of Solar Intelligence for Solar Media, says "The focus on new technology, both due to upgrades and when incorporated in new fab builds, since 2015 looks very different to the technologies that drove PV equipment spending above $10 billion during 2010 and 2011.  At the c-Si stage, the most obvious change has come from PERC, and by 2019, most of the capacity for both p-type mono and multi will have shifted to include rear passivation deposition (PERC), with many of the companies having a clear roadmap to bifaciality. Moving into 2020, this will become mainstream for the industry. Indeed, anyone making c-Si cells with efficiencies below 20% is likely to be left with low-cost selling options then."

"Monocrystalline PERC and Bifacial cell applications drove our business last year and with the addition of Heterojunction optimization solutions to our portfolio, we are well positioned as the solution provider for advanced cell measurement and efficiency optimization," said Michael Heaven, Aurora's CEO.  "The company is discussing new orders for plant expansions with existing customers and conducting testing activities under NDA's with several new prospective clients and expects additions to the order pipeline disclosed in the November 20, 2017 release in the next several weeks and months."

About Aurora Solar Technologies:

Aurora's mission is to deliver exceptional results to the photovoltaic industry through measurement and control of critical processes during solar cell manufacturing.

We measure and map the results of critical cell fabrication processes, providing real-time visualization of material properties and true production tool performance. Our products provide process engineers and production-line operators with the means to rapidly detect and correct process excursions, material faults, limit variations, and optimize processes, thereby eliminating yield-reducing and profit-killing product variation.

We are creating the standard for quality control systems for the global photovoltaic industry. 

Headquartered in North Vancouver, Canada, and founded by experienced leaders in process measurement, semiconductor manufacturing and industrial automation, the Company's shares are listed on the TSX Venture Exchange and trade under the symbol "ACU". The Company was formerly "ACT Aurora Control Technologies". For more information, Aurora's website is located at www.aurorasolartech.com.

For further information contact:

Michael Heaven, P.Eng., MBA
President & Chief Executive Officer
Aurora Solar Technologies Inc.
Phone: +1 (778) 241-5000 
info@aurorasolartech.com

Investor Relations contact:
Nina Lafleur
Phone: +1 (604) 679-9964
info@aurorasolartech.com

Paradox Public Relations
Phone: +1 (514) 341-0408
info@paradox-pr.ca

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Some statements in this news release contain forward­looking information. These statements address future events and conditions and, as such, involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the statements. The Company does not assume the obligation to update any forward­looking statement.




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Aurora Solar Technologies Inc. via Globenewswire

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

World Conference on Lung Cancer Monday Press Conference: Clinical Research Results and Gender Differences in Lung Cancer Survival24.9.2018 20:26Pressemelding

TORONTO, Sept. 24, 2018 (GLOBE NEWSWIRE) -- At today’s press conference at the International Association for the Study of Lung Cancer’s (IASLC’s) 19th World Conference on Lung Cancer (WCLC), conference co-president Dr. Andrea Bezjak, M.D., FRCPC, MSc, professor in the Departments of Radiation Oncology and Health Policy, Management and Evaluation at the University of Toronto and staff radiation oncologist at Princess Margaret Cancer Centre, summarized the wide-ranging study topics presented in today’s conference, from significant clinical research findings to gender differences in lung cancer survival. IMpower132 study shows atezolizumab in combination with carboplatin and pemetrexed improves survival in Stage IV non-squamous NSCLC Recent findings from the IMpower132 study, presented by Vassiliki A. Papadimitrakopoulou, M.D., chief of the Section of Thoracic Medical Oncology at MD Anderson Cancer Center, demonstrate that the use of atezolizumab in combination with carboplatin as first-l

Bombardier CRJ Series Certified for Higher Maintenance Intervals24.9.2018 18:00Pressemelding

MONTREAL, Sept. 24, 2018 (GLOBE NEWSWIRE) -- Bombardier Commercial Aircraft announced today that the Federal Aviation Agency (FAA) has granted approval for the maintenance intervals escalation of the CRJ700, CRJ900 and CRJ1000 aircraft. The line maintenance interval (A-check) is extended to 800 flight hours, and the heavy maintenance interval (C-check) at 8,000 flight hours. “With the longest maintenance intervals on the regional jet market, the CRJ aircraft family continues to deliver more value to operators, along with its excellent reliability and its proven outstanding operational capability”, said Charles Comtois, Head of CRJ Series Program, Bombardier Commercial Aircraft. “We are thrilled that our operators are benefitting from our continuous improvement mindset as with this evolution, the CRJ Series operators can now take advantage of 14 per cent less maintenance days, meaning more days of revenue flying.” The maintenance intervals have doubled since the launch of the CRJ aircra

Mitratech Launches Latest TeamConnect ELM Innovations at Interact24.9.2018 16:01Pressemelding

Full Integration of TAP Workflow Automation, New Business Intelligence Module and Deeper MS Office Integration Enhance Collaboration and Reporting AUSTIN, Texas, Sept. 24, 2018 (GLOBE NEWSWIRE) -- Mitratech released the next version of TeamConnect at Interact, the company’s customer-focused annual event in Austin. The latest version of the award-winning ELM platform now includes: Full Integration with TAP Workflow Automation Business Intelligence reporting Deeper Microsoft® Office integration Today, TeamConnect integrates with TAP Workflow Automation and redefines every aspect of data analytics and reporting through the TeamConnect Business Intelligence (BI) module. With the addition of the TAP Workflow Automation Platform recently acquired in April, Mitratech’s TeamConnect platform can now bring people, processes, and information together like never before, by leveraging TAP’s easy-to-use workflow automation engine to extend TeamConnect’s reach across the entire enterprise. TAP was des

Colliers International Appoints Christopher Galvin to Its Board of Directors24.9.2018 16:00Pressemelding

TORONTO, Sept. 24, 2018 (GLOBE NEWSWIRE) -- Colliers International Group Inc. (NASDAQ and TSX: CIGI) (“Colliers”) today announced the appointment of Mr. Christopher Galvin to its Board of Directors, effective immediately. Mr. Galvin previously served as the Chairman and co-founder of Harrison Street Real Estate Capital LLC, one of the largest real estate investment firms dedicated to the education, healthcare and storage sectors. Colliers acquired a 75% interest in Harrison Street earlier this year. Mr. Galvin presently serves as Chairman or board member of Uniquesoft, LLC, Velocidata, evolve24, Three Ocean Partners and MCR-Aerodyne, Inc. Additionally, Mr. Galvin is a member of the Executive Committee of Northwestern University’s Board of Trustees, and the Boards of Trustees of the American Enterprise Institute, the Legion D’honneur, and Tsinghua University School of Economics Management Advisory Council, among others. Mr. Galvin has previously served in a variety of executive leadersh

Seclore Offers the First Open Data-Centric Security Platform24.9.2018 15:00Pressemelding

Easily leverage best-of-breed data protection solutions and existing Enterprise systems for an automation-first approach to data protection and tracking MILPITAS, Calif., Sept. 24, 2018 (GLOBE NEWSWIRE) -- Seclore, providers of the industry’s first browser-based Rights Management solution, today announced the release of Seclore’s Data-Centric Security Platform (DCSP). A first-of-its kind platform, it is designed to give customers an open, integrated and automated Data-Centric Security approach to discover, identify, protect and track sensitive data. The automation and agility of the platform enables organizations to remove the limitations of point solutions while increasing the security of sensitive data. At the core of the Seclore DCSP, is the Seclore Unified Policy Manager, the central engine for orchestrating policy management, identity federation, and usage data consolidation. Learn more about the Seclore Data-Centric Security Platform “As data grows exponentially and is stored and

XBiotech Announces Completion of U.S. Enrollment in Phase 2 Multicenter Study Evaluating Bermekimab in Patients with Hidradenitis Suppurativa24.9.2018 14:30Pressemelding

AUSTIN, Texas, Sept. 24, 2018 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced today that it had completed enrollment in the U.S. for its Phase 2, open label clinical study evaluating subcutaneous administration of bermekimab in patients with moderate to severe Hidradenitis Suppurativa (HS). Enrollment has exceeded the planned limit for the study in just over two months, significantly outpacing expectations. XBiotech plans to accept a limited number of additional patients in Europe prior to study completion. John Simard, Chairman & CEO of XBiotech, commented, “We are very pleased by the enrollment rate we have seen in this study. Patient availability has been well beyond what was predicted. I believe this speaks to the need for new treatment options for this debilitating disease. I want to thank all of the patients and clinical sites for their ongoing participation in this study.” The phase 2 study involves a 13-week treatment regimen. Two groups of patients are being treated

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom